IPP and prostate cancer: In contrast, Vγ9Vδ2 T cells offer a valuable opportunity for dual targeting and activation by stimulatory tumor cells and phosphoantigens, such as IPP, generated by nBPs such as ZOL that are commonly given to men with advanced prostate cancer (16).